227 related articles for article (PubMed ID: 21725649)
1. [Therapy-refractory overactive bladder: alternative treatment approaches].
Knüpfer S; Hamann M; Naumann CM; Melchior D; Jünemann KP
Urologe A; 2011 Jul; 50(7):806-9. PubMed ID: 21725649
[TBL] [Abstract][Full Text] [Related]
2. [Treatment for refractory non-neurogenic overactive bladder].
Gamé X; Phé V
Prog Urol; 2020 Nov; 30(14):920-930. PubMed ID: 33220820
[TBL] [Abstract][Full Text] [Related]
3. [Management of overactive bladder in women].
Peyronnet B; Rigole H; Damphousse M; Manunta A
Prog Urol; 2015 Nov; 25(14):877-83. PubMed ID: 26169251
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
[TBL] [Abstract][Full Text] [Related]
5. The evaluation and management of refractory neurogenic overactive bladder.
Kurpad R; Kennelly MJ
Curr Urol Rep; 2014 Oct; 15(10):444. PubMed ID: 25118853
[TBL] [Abstract][Full Text] [Related]
6. [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity].
Leicht W; Hampel C; Thüroff J
Urologe A; 2012 Mar; 51(3):348-51. PubMed ID: 22399111
[TBL] [Abstract][Full Text] [Related]
7. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
Bach P; Wormland RT; Möhring C; Goepel M
Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
[TBL] [Abstract][Full Text] [Related]
8. Overactive Bladder.
White N; Iglesia CB
Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
[TBL] [Abstract][Full Text] [Related]
9. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
[TBL] [Abstract][Full Text] [Related]
10. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
11. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
Tubaro A; Puccini F; De Nunzio C
Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
13. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
[TBL] [Abstract][Full Text] [Related]
14. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
Yang G; Xu Y; Qu G; Zhang Y
PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
[TBL] [Abstract][Full Text] [Related]
15. Management of refractory OAB in the non-neurogenic patient.
Wadie BS
Curr Urol Rep; 2014 Sep; 15(9):438. PubMed ID: 25015301
[TBL] [Abstract][Full Text] [Related]
16. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature.
Kasman A; Stave C; Elliott CS
Neurourol Urodyn; 2019 Nov; 38(8):2083-2092. PubMed ID: 31483070
[TBL] [Abstract][Full Text] [Related]
18. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
19. Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex.
Su X; Nickles A; Nelson DE
BMC Urol; 2015 Jun; 15():50. PubMed ID: 26055982
[TBL] [Abstract][Full Text] [Related]
20. What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017.
Malde S; Fry C; Schurch B; Marcelissen T; Averbeck M; Digesu A; Sahai A
Neurourol Urodyn; 2018 Jun; 37(S4):S108-S116. PubMed ID: 30133790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
